Willy Barton / Shutterstock.com
25 August 2022Big PharmaSarah Speight
GSK presses court to deny Teva’s ‘skinny label’ petition
Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
4 October 2022 Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Editor's picks
Editor's picks
Big Pharma
4 October 2022 Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.
Big Pharma
4 October 2022 Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
Big Pharma
30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
article
16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.